Off-Label Promotion Settlement Includes Optional Preclearance Process

Amarin may submit up to two proposed communications annually about unapproved use of Vascepa, and FDA must respond with any concerns within 60 calendar days.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from United States

More from North America